Literature DB >> 9323713

Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs.

A W Stitt1, C He, S Friedman, L Scher, P Rossi, L Ong, H Founds, Y M Li, R Bucala, H Vlassara.   

Abstract

BACKGROUND: Advanced glycation endproducts (AGEs) are implicated in the pathogenesis of atherosclerotic vascular disease of diabetic and nondiabetic etiology. Recent research suggests that advanced glycation of ApoB contributes to the development of hyperlipidemia. AGE-specific receptors, expressed on vascular endothelium and mononuclear cells, may be involved in both the clearance of, and the inflammatory responses to AGEs. The aim of this study was to examine whether there is a relationship between serum AGE-ApoB and AGEs in arterial tissue of older normolipidemic nondiabetic patients with occlusive atherosclerotic disease, compared with age-matched and younger asymptomatic persons.
MATERIALS AND METHODS: Serum AGE-ApoB was measured by ELISA in 21 cardiac bypass patients. Furthermore, an AGE-specific monoclonal antibody, and polyclonal antibodies against anti-AGE-receptor (anti-AGE-R) 1 and 2 were used to explore the localization and distribution of AGEs and AGE-R immunoreactivity (IR) in arterial segments excised from these patients.
RESULTS: Serum AGE-ApoB levels were significantly elevated in the asymptomatic, older population, compared with those in young healthy persons (259 +/- 24 versus 180 +/- 21 AGE U/mg of ApoB, p < 0.01). Higher AGE-ApoB levels were observed in those patients with atherosclerosis (329 +/- 23 versus 259 +/- 24 AGE U/mg ApoB, p < 0.05). Comparisons of tissue AGE-collagen with serum AGE-ApoB levels showed a significant correlation (r = 0.707, p < 0.01). In early lesions, AGE-IR occurred mostly extracellularly. In fatty streaks and dense, cellular atheromatous lesions, AGE-IR was visible within lipid-containing smooth muscle cells and macrophages, while in late-stage, acellular plaques, AGE-IR occurred mostly extracellularly. AGE-R1 and -R2 were observed on vascular endothelial and smooth-muscle cells and on infiltrating mononuclear cells in the early-stage lesions, whereas in dense, late-stage plaques, they colocalized mostly with lipid-laden macrophages. On tissue sections, scoring of AGE-immunofluorescence correlated with tissue AGE and plasma AGE-ApoB.
CONCLUSIONS: (1) The correlation between arterial tissue AGEs and circulating AGE-ApoB suggests a causal link between AGE modification of lipoproteins and atherosclerosis. AGE-specific receptors may contribute to this process. (2) Serum AGE-ApoB may serve to predict atherosclerosis in asymptomatic patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9323713      PMCID: PMC2230092     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  38 in total

1.  Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins.

Authors:  Y M Li; T Mitsuhashi; D Wojciechowicz; N Shimizu; J Li; A Stitt; C He; D Banerjee; H Vlassara
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

2.  Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition.

Authors:  J L Goldstein; Y K Ho; S K Basu; M S Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1979-01       Impact factor: 11.205

3.  Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex.

Authors:  H Vlassara; Y M Li; F Imani; D Wojciechowicz; Z Yang; F T Liu; A Cerami
Journal:  Mol Med       Date:  1995-09       Impact factor: 6.354

4.  Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody.

Authors:  S Kume; M Takeya; T Mori; N Araki; H Suzuki; S Horiuchi; T Kodama; Y Miyauchi; K Takahashi
Journal:  Am J Pathol       Date:  1995-09       Impact factor: 4.307

5.  Protein glycation and fluorescent material in human atheroma.

Authors:  J V Hunt; J T Skamarauskas; M J Mitchinson
Journal:  Atherosclerosis       Date:  1994-12       Impact factor: 5.162

6.  Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits.

Authors:  H Vlassara; H Fuh; T Donnelly; M Cybulsky
Journal:  Mol Med       Date:  1995-05       Impact factor: 6.354

7.  Factors regulating the activities of the low density lipoprotein receptor and the scavenger receptor on human monocyte-macrophages.

Authors:  A M Fogelman; M E Haberland; J Seager; M Hokom; P A Edwards
Journal:  J Lipid Res       Date:  1981-09       Impact factor: 5.922

8.  Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor.

Authors:  R Bucala; R Mitchell; K Arnold; T Innerarity; H Vlassara; A Cerami
Journal:  J Biol Chem       Date:  1995-05-05       Impact factor: 5.157

9.  Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits.

Authors:  W Palinski; T Koschinsky; S W Butler; E Miller; H Vlassara; A Cerami; J L Witztum
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-05       Impact factor: 8.311

10.  Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif.

Authors:  Y M Li; A X Tan; H Vlassara
Journal:  Nat Med       Date:  1995-10       Impact factor: 53.440

View more
  28 in total

Review 1.  Advanced glycation: an important pathological event in diabetic and age related ocular disease.

Authors:  A W Stitt
Journal:  Br J Ophthalmol       Date:  2001-06       Impact factor: 4.638

Review 2.  Glycoxidation and diabetic complications: modern lessons and a warning?

Authors:  Helen Vlassara; Jaime Uribarri
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

3.  Increased levels of advanced glycation endproducts in the lenses and blood vessels of cigarette smokers.

Authors:  I D Nicholl; A W Stitt; J E Moore; A J Ritchie; D B Archer; R Bucala
Journal:  Mol Med       Date:  1998-09       Impact factor: 6.354

Review 4.  Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms.

Authors:  Alin Stirban; Thomas Gawlowski; Michael Roden
Journal:  Mol Metab       Date:  2013-12-07       Impact factor: 7.422

Review 5.  AGE restriction in diabetes mellitus: a paradigm shift.

Authors:  Helen Vlassara; Gary E Striker
Journal:  Nat Rev Endocrinol       Date:  2011-05-24       Impact factor: 43.330

6.  Nutrition, metabolism and colorectal cancer.

Authors:  G Misciagna; M G Caruso; M Trevisan
Journal:  Genes Nutr       Date:  2008-04       Impact factor: 5.523

7.  Simple non-invasive assessment of advanced glycation endproduct accumulation.

Authors:  R Meerwaldt; R Graaff; P H N Oomen; T P Links; J J Jager; N L Alderson; S R Thorpe; J W Baynes; R O B Gans; A J Smit
Journal:  Diabetologia       Date:  2004-07-09       Impact factor: 10.122

Review 8.  Advanced glycation end products (AGE) and diabetes: cause, effect, or both?

Authors:  Helen Vlassara; Jaime Uribarri
Journal:  Curr Diab Rep       Date:  2014-01       Impact factor: 4.810

9.  Impact of in vivo glycation of LDL on platelet aggregation and monocyte chemotaxis in diabetic psammomys obesus.

Authors:  Monika Zoltowska; Edgard Delvin; Ehud Ziv; Noel Peretti; Manon Chartré; Emile Levy
Journal:  Lipids       Date:  2004-01       Impact factor: 1.880

Review 10.  The role of advanced glycation end products in the development of atherosclerosis.

Authors:  Melpomeni Peppa; Jaime Uribarri; Helen Vlassara
Journal:  Curr Diab Rep       Date:  2004-02       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.